Mass High Tech -- Sanofi-Aventis SA’s CEO said that the company will not rush to acquire Genzyme Corp., at a conference in London Wednesday. But, Sanofi CEO Chris Viebacher said he still sees a decent chance to buy the company at a reasonable price eventually, speaking at the Bank of America-Merrill Lynch Global Healthcare Conference. The French pharma has made an initial bid of $18.5 billion, which Genzyme CEO Henri Termeer has said is too low.
